Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL354706 | 0.83 | DPP4 (0.41) | DPP4DPP8DPP7 | |
| SCHEMBL353690 | 0.83 | DPP4 (0.41) | DPP4DPP8DPP7 | |
| SCHEMBL1445688 | 0.83 | DPP4 (0.41) | DPP4DPP8DPP7 | |
| Hydrochloric Acid SCHEMBL5079153 | 0.82 | DPP4 (0.40) | DPP4DPP8DPP7 | |
| Hydrochloric Acid SCHEMBL5706355 | 0.82 | DPP4 (0.40) | DPP4DPP8DPP7 | |
| Hydrochloric Acid SCHEMBL27529254 | 0.82 | DPP4 (0.40) | DPP4DPP8DPP7 | |
| SCHEMBL25430553 | 0.79 | MAPT (0.46) | MAPT | |
| SCHEMBL5493822 | 0.77 | DPP4 (0.33) | DPP4 | |
| Fumaric Acid SCHEMBL4948911 | 0.77 | DPP4 (0.36) | DPP4DPP8DPP7 | |
| Fumaric Acid SCHEMBL4955812 | 0.77 | DPP4 (0.36) | DPP4DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166579-B2 | Prodrugs of DP IV-inhibitors | PROSIDION LIMITED (GB) | 2007-01-23 | — | — | US | claimed |
| US-7053055-B2 | Compounds of unstable DP IV-inhibitors | PROSIDION LTD. (GB) | 2006-05-30 | — | — | US | claimed |
| US-20050203030-A1 | Novel effectors of dipeptidyl peptidase IV | PROSIDION LIMITED (GB) | 2005-09-15 | — | — | US | claimed |
| CN-1636593-A | Novel effectors of dipeptidyl peptidase IV | PROSIDION LTD (GB) | 2005-07-13 | — | — | CN | claimed |
| US-6890905-B2 | Methods for improving islet signaling in diabetes mellitus and for its prevention | PROSIDION LIMITED (GB) | 2005-05-10 | — | — | US | claimed |
| EP-1398030-A2 | Dipeptidyl peptidase IV effectors | Probiodrug AG (DE) | 2004-03-17 | — | — | EP | claimed |
| EP-3023095-B2 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2023-11-08 | — | — | EP | disclosed |
| US-11548916-B2 | Anti-infective compound | EBERHARD KARLS UNIVERSITAET TUEBINGEN (DE) | 2023-01-10 | — | — | US | disclosed |
| US-20210024580-A1 | Novel Anti-Infective Compound | EBERHARD KARLS UNIVERSITAET TUEBINGEN (DE) | 2021-01-28 | — | — | US | disclosed |
| EP-3738585-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2020-11-18 | — | — | EP | disclosed |
| US-10774113-B2 | Anti-infective compound | EBERHARD KARLS UNIVERSITAET TUEBINGEN (DE) | 2020-09-15 | — | — | US | disclosed |
| EP-3366283-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | Novartis AG (CH) | 2018-08-29 | — | — | EP | disclosed |
| US-20180155397-A1 | Novel Anti-Infective Compound | EBERHARD KARLS UNIVERSITAET TUEBINGEN (DE) | 2018-06-07 | — | — | US | disclosed |
| WO-2003099279-A1 | COMBINATION OF A DPP IV INHIBITOR AND A CARDIOVASCULAR COMPOUND | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | disclosed |
| EP-1304327-A2 | Glutamine-thiazolidide and -pyrrolidide and their use as dipeptidylpeptidase IV inhibitors | Probiodrug AG (DE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2003014145-A2 | PEPTIDES THAT BIND TO ATHEROSCLEROTIC LESIONS | NOVARTIS AG (CH) | 2003-02-20 | — | — | WO | disclosed |
| EP-1259246-A2 | USE OF DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2002-11-27 | — | — | EP | disclosed |
| EP-1214936-A2 | Use of thiazolidin- or pyrrolidin-derivatives of aminoacids as antihyperglycemic agents | Probiodrug AG (DE) | 2002-06-19 | — | — | EP | disclosed |
| US-20010025023-A1 | Inhibition of beta cell degeneration | NOVO NORDISK A/S (DK) | 2001-09-27 | — | — | US | disclosed |
| WO-2001062266-A2 | USE OF DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024580-A1 | Novel Anti-Infective Compound | FABP2, VIP, LCT | MAPT 3511/4885SLC7A5 2532/4885DPP4 110/4885 |
| US-20180155397-A1 | Novel Anti-Infective Compound | FABP2, VIP, LCT | MAPT 3511/4885SLC7A5 2532/4885DPP4 110/4885 |
| US-11548916-B2 | Anti-infective compound | LCT, VIP, TLR5 | MAPT 3122/4885SLC7A5 3052/4885DPP4 107/4885 |
| US-10774113-B2 | Anti-infective compound | LCT, VIP, TLR5 | MAPT 3122/4885SLC7A5 3052/4885DPP4 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.